ERVMER34-1 Inhibitors
Chemical inhibitors of ERVMER34-1 target various signaling pathways and cellular processes to inhibit the function of this protein. Palbociclib directly halts the progression of the cell cycle by selectively inhibiting cyclin-dependent kinases CDK4 and CDK6, which are essential for cell cycle progression and thus for the activity of ERVMER34-1 in proliferation. Trametinib, by blocking the MAPK/ERK pathway, suppresses the signal transduction related to cell growth and differentiation, which are processes in which ERVMER34-1 is involved. Similarly, Erlotinib's inhibition of the epidermal growth factor receptor tyrosine kinase impacts downstream signaling pathways that involve ERVMER34-1, leading to the inhibition of processes like cell growth and proliferation. Rapamycin's role as an mTOR inhibitor disrupts the activity of ERVMER34-1 related to cell growth and metabolism by inhibiting mTOR activity.
Sorafenib, as a multikinase inhibitor, targets RAF kinases and others, thus affecting downstream signaling that involves ERVMER34-1 in cell proliferation and angiogenesis. Imatinib, while primarily known for its inhibition of BCR-ABL tyrosine kinase, also impacts the function of ERVMER34-1 by inhibiting PDGFR, which can play a role in signaling pathways involving ERVMER34-1. Sunitinib's inhibition of receptor tyrosine kinases, including PDGFR and VEGFR, downregulates pathways in which ERVMER34-1 may be involved. Gefitinib's inhibition of EGFR impedes pathways involving ERVMER34-1, leading to its functional inhibition. Bortezomib disrupts various cellular processes, including those involving ERVMER34-1, by inhibiting the proteasome and preventing the degradation of regulatory proteins. Dasatinib interferes with multiple signaling pathways by inhibiting SRC-family tyrosine kinases, thus impacting the function of ERVMER34-1. Crizotinib, by inhibiting ALK and ROS1, suppresses downstream signaling pathways involving ERVMER34-1. Lastly, Venetoclax, as a BCL-2 inhibitor, leads to the apoptosis of cells expressing ERVMER34-1, thus reducing the population of cells where ERVMER34-1 is active and functionally inhibiting the protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Since ERVMER34-1 has been implicated in cell cycle progression, inhibiting CDK4/6 can halt the cell cycle, thereby functionally inhibiting ERVMER34-1 by preventing its associated cell proliferation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that blocks the MAPK/ERK pathway. As ERVMER34-1 is known to be involved in signal transduction related to cell growth and differentiation, inhibiting the MAPK/ERK pathway would suppress the signals leading to these functions, thereby inhibiting the activity of ERVMER34-1. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that can inhibit the epidermal growth factor receptor tyrosine kinase. By blocking this receptor, the downstream signaling pathways involving ERVMER34-1 in cell growth and proliferation are inhibited. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and since ERVMER34-1 is associated with cell growth and metabolism, inhibiting mTOR activity can lead to the inhibition of the protein's function in these processes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multikinase inhibitor that targets RAF kinases, among others. By inhibiting RAF kinases, the downstream signaling involving ERVMER34-1 in cell proliferation and angiogenesis is inhibited. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor. Although it is primarily used for certain types of leukemia, it also inhibits PDGFR, which can play a role in signaling pathways involving ERVMER34-1, thereby inhibiting the protein's function. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, which includes PDGFR and VEGFR. Inhibition of these receptors can lead to downregulation of pathways in which ERVMER34-1 may be involved, leading to functional inhibition of the protein. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the proliferation and survival of cancer cells. By inhibiting EGFR, this would impede the pathways that potentially involve ERVMER34-1, resulting in its functional inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disrupt various cellular processes, including those that involve ERVMER34-1, by preventing the degradation of proteins that regulate the cell cycle and survival, thus inhibiting the function of ERVMER34-1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is an SRC-family tyrosine kinase inhibitor. By inhibiting SRC kinases, it can interfere with multiple signaling pathways, potentially including those associated with ERVMER34-1, and consequently inhibit the protein's function. | ||||||